Purpose Genome-wide association studies (GWAS) have identified dozens of single-nucleotide polymorphisms (SNPs) associated with breast cancer. Few studies focused on young-onset breast cancer, which exhibits etiologic and tumor-type differences from older-onset disease. Possible confounding by prenatal effects of the maternal genome has also not been considered. Methods Using a family-based design for breast cancer before age 50, we assessed the relationship between breast cancer and 77 GWAS-identified breast cancer risk SNPs. We estimated relative risks (RR) for inherited and maternally mediated genetic effects. We also used published RR estimates to calculate genetic risk scores and model joint effects. Results Seventeen of the candidate SNPs were nominally associated with young-onset breast cancer in our 1296 nonHispanic white affected families (uncorrected p value\0.05). Top-ranked SNPs included rs3803662-A (TOX3, RR = 1.39; p = 7.0 9 10 -6 ), rs12662670-G (ESR1, RR = 1.56; p = 5.7 9 10 -4 ), rs2981579-A (FGFR2, RR = 1.24; p = 0.002), and rs999737-G (RAD51B, RR = 1.37; p = 0.003). No maternally mediated effects were found. A risk score based on all 77 SNPs indicated that their overall relationship to young-onset breast cancer risk was more than additive (additive-fit p = 2.2 9 10 -7
Introduction
In the search for genetic risk variants associated with breast cancer, dozens of genome-wide association studies (GWAS) have identified more than a hundred single-nucleotide polymorphisms (SNPs) . Many of these susceptibility loci have been confirmed in other study samples and across racial groups [34] [35] [36] [37] [38] [39] , but relatively few studies were designed to examine whether these GWAS 'hits' are associated with young-onset breast cancer [1, 16, 23, [40] [41] [42] [43] . Given evidence that age modifies the association between breast cancer and some non-genetic risk factors [44] [45] [46] [47] and that younger cases are more likely to have strong family histories of the disease [48] , additional studies of the genetic determinants of young-onset breast cancer are warranted. Young-onset breast cancer is often defined as breast cancer before the age of 50, as this age is both a proxy for menopausal status and an inflection point for incidence trends in US women [44] . Young-onset disease tends to be relatively more aggressive and difficult to treat [49, 50] , and includes a higher fraction of triple-negative breast cancers [51] , which may have distinct genetic risk factors [52] [53] [54] [55] [56] .
An early GWAS of young-onset breast cancer identified one risk-associated SNP in GLG1 [16] . In a larger and more recent GWAS of young-onset breast cancer, Ahsan et al. [1] identified 96 SNPs with genome-wide significant p values, all of which were located in six regions previously linked to breast cancer risk unrestricted by age. In total, the authors found that 32 of 83 previously identified GWAS hits were associated with young-onset disease (p \ 0.05).
Family-based designs are feasible for diseases that occur at young ages and offer certain advantages over casecontrol studies, including robustness to bias due to population stratification and the ability to assess maternally mediated or imprinting effects [57, 58] . We previously conducted a family-based GWAS of young-onset breast cancer, in which we identified 9 SNPs with unadjusted p values \10 -5 , including several novel loci [59] . Here, we further investigate the role of 77 known risk variants by reporting their individual associations with youngonset breast cancer and exploring whether their joint effects follow additive or multiplicative risk models. The selected risk variants were previously identified by Mavaddat et al. [60] as having an association with breast cancer at p \ 5 9 10 -8
. We also examined maternally mediated effects [58] for the same 77 SNPs to assess the influence of the mother's genotype acting prenatally on her daughter, controlling for the daughter's genotype. Because mother's and daughter's genotypes are correlated, maternally mediated genetic effects could confound inherited-gene effects and may have biased some of the previously observed GWAS associations.
Methods

Study participants
Young-onset breast cancer cases and their families were recruited as part of the Sister Study and Two Sister Study.
The Sister Study is a prospective cohort of women who had one or more sisters diagnosed with breast cancer, but had never had breast cancer themselves at enrollment (2003) (2004) (2005) (2006) (2007) (2008) (2009) When we enrolled women in the Sister Study, we asked them the age and date of diagnosis of their affected sister. Proband sisters whose breast cancer was diagnosed before age 50 and within the previous four years were eligible for inclusion in the Two Sister Study. We developed a familybased genetic study by asking an unaffected sister to forward a study invitation to her eligible affected sister and then asking all of the participating young-onset cases to forward a letter from us to any living parents, asking them to provide saliva samples. If one or both parents were unavailable, we genotyped DNA from the blood or saliva from unaffected sister(s) participating in the Sister Study. In total, 3331 individuals from 1477 families were genotyped.
All participants provided written or verbal consent, and the study was approved by the National Institute of Environmental Health Sciences and the Copernicus Group Institutional Review Boards. The GWAS data are publically accessible (https://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000678.v1.p1). None of the Sister Study or Two Sister Study participants were included in any previously published pooled or meta-analyses.
In addition to providing DNA samples, participants completed computer-assisted telephone interviews about various health-related and lifestyle factors. All cases were asked about their breast cancer diagnosis and treatment and to authorize release of their medical records. Tumor information, including invasiveness and estrogen receptor (ER) status, was extracted from the medical records for most cases (85-90%). We relied on self-report for the remainder after observing that Sister Study participants could recall their status with reasonable accuracy (positive predictive values of 99, 64, 99, and 84% for invasive, in situ, ER?, and ER-breast cancers, respectively). We also reviewed medical records for BRCA1/2 findings and asked participants to report the results of any BRCA1/2 mutation tests. A case was assumed to be BRCA1/2 positive if she had a positive test or if her sister had a positive test, but the case had not been tested.
Genotyping analysis
DNA samples were collected from saliva (80%), whole blood (19%), or blood clot (1%) and shipped to the Johns Hopkins University Center for Inherited Disease Research for genotyping, with subsequent quality control carried out by the Genetics Coordinating Center at the University of Washington. After extraction, DNA samples were processed using 96-well plates, with family members assigned to the same plate. We included 76 HapMap controls and 74 duplicate samples, balanced across plates. All samples were analyzed using the Illumina OmniExpress plus HumanExome-8v1-2 array, which included 964,193 SNPs.
Genotyping revealed that 11 of the sister-pairs were half-sisters. The 11 unaffected half-sisters were excluded. Because numbers were inadequate for sufficiently wellparameterized analyses of minority categories, we limited analyses to the majority category of 1296 non-Hispanic white families (Table 1) . No additional participants were excluded, as individuals' missing call rates were all \2%, and duplicate discordance and Mendelian inconsistency rates were low (7.9 9 10 -6 per SNP per duplicate pair, and 0.0003 per SNP, respectively). Individuals with chromosomal anomalies (n = 6) were assigned missing values for affected regions.
Forty of the 77 candidate SNPs were directly genotyped on our arrays. All met the inclusion criteria in non-Hispanic whites: call rates C97%, B1 discordant call in 74 study duplicates, B5 Mendelian errors, and Hardy-Weinberg equilibrium p values C1 9 10 -6 among founders. Two SNPs with a minor allele frequency \1% were excluded from our assessment of individual SNP effects, but were retained in the genetic risk score analysis.
Imputation analysis
Imputation analyses were conducted at the University of Washington's Genetics Coordinating Center using data from the 1000 Genomes Project [61] . Haplotypes were prephased using SHAPEIT2 [62] to improve efficiency and make use of known family structures. Imputation was then conducted using IMPUTE (v2.3.0) [63] . The imputation was highly accurate, with good concordance between measured and masked but imputed as most-probable genotypes (99.7 and 98.0% when minor allele frequencies were \5 and C5%, respectively).
In total, 22 million loci were imputed, including 37 of the non-genotyped SNPs from our list of 77. We imputed based on the most probable imputed genotype. If none of an individual's estimated genotype probabilities exceeded 90%, the genotype for that locus was considered missing.
Statistical analysis
Individual SNP effects
For each of the 75 typed candidate SNPs (38 genotyped, 37 imputed), we recorded the odds ratio (OR) as reported in Mavaddat et al. [60] and noted which allele was associated with increased breast cancer risk. We then tested the association between each of the candidate SNPs and young-onset breast cancer using a likelihood-based log-linear model to assess transmission distortion within families [58] . Briefly, this conditional model examines whether the relative frequencies of particular offspring genotypes at a di-allelic locus are consistent with Mendelian inheritance. Expected frequencies are modeled using a multinomial distribution with six mating-type parameters, which impose conditioning on parental genotypes, and fifteen possible case-parent outcomes. Using likelihood ratio tests (v 2 distribution), we tested the association between each SNP and young-onset breast cancer by comparing models with and without a term for the relative risk of the offspring's genetic effect. We estimated the relative risks (RR) using Poisson regression. If either or both parents were unavailable, an expectationmaximization algorithm was applied to maximize the likelihood [64, 65] . Because we selected these SNPs based on evidence that they were associated with breast cancer, we did not correct p values for multiple comparisons, but used a = 0.05 to evaluate statistical significance.
To facilitate comparisons with Mavaddat et al. [60] and other prior studies, we estimated RRs for each SNP in relation to the previously established risk allele. We assumed a log-additive model, coding genotype as the number of copies of the risk allele carried by the affected offspring. All analyses used LEM (http://members.home. nl/jeroenvermunt/#Software) and R (v3.2.1). We performed t-tests to compare the risk ratio observed in our study (representative of the young-onset breast cancer effect estimate) and the pooled odds ratio reported by Mavaddat et al. [60] (representative of the overall breast cancer effect estimate).
We also assessed the effects of each SNP in family subsets limited to invasive, ER?, or premenopausal breast cancer and in the subset of families not known to carry BRCA1/2 mutations. Small numbers precluded assessments for the complementary categories. We also estimated RRs for maternally mediated effects [58] .
As secondary analyses, we considered 89 other SNPs known to be associated with breast cancer risk. Additional details of the SNP selection process and results can be found in the Supplementary Materials.
Genetic risk scores
In addition to assessing their main effects, we also assessed the efficacy of our 77-SNP set by calculating both multiplicative and additive scores and comparing their model fits and predictive properties. The multiplicative genetic risk score was calculated as:
, where OR i is the previously reported OR for one copy of the risk variant at SNP i and x i is the number of copies of that risk variant carried by the individual. The summation is over k = 77 candidate SNPs. Therefore, if 1) the effect size for each SNP in our study is equal to the previously reported effect size, 2) the joint effect of more than one copy is multiplicative, and 3) the joint effect of multiple SNPs is multiplicative, then the risk score will equal the ln-OR for the 77-SNP set. Thus, the coefficient of P i=1 k x i ln (OR i ) is 1.0 under a multiplicative joint effects model. To the extent that the multiplicative genetic risk score and the ln-odds of developing young-onset breast cancer differ (as when the b coefficient differs from 1), there is a departure from multiplicity. The multiplicative joint effects model fit can be tested by comparing b to 1.0 using a Wald test (b-1 divided by standard error). One can also test whether the multiplicative genetic risk score is associated with young-onset breast cancer by comparing b to 0, again using a Wald test.
The additive genetic risk score was calculated as:
. In this study, if (1) the effect size for each SNP in our study is equal to the previously reported effect size, (2) the effect of having more than one copy of the risk allele is additive, and (3) the joint effect of multiple SNPs is additive, then that risk score equals the ln-OR for young-onset breast cancer. Thus, the true coeffi-
is 1.0 under a fully additive joint effects model. As with the multiplicative model, the additive model fit can be tested by comparing b to 1.0 using a Wald test, and the association between the additive risk score and young-onset breast cancer can be tested by comparing b to 0. We calculated the effect estimate (b) per unit increase in risk score using a conditional logistic regression model to compare cases to unaffected sister controls. When both sisters were genotyped, we compared them directly. If the unaffected sister was not genotyped but both parents were, we compared cases to an equally likely, complementary pseudo-sister whose genotype was defined by her parents' non-transmitted alleles. Altogether, we included 850 casesister or case-pseudo-sister-pairs in the risk scores analyses. For sporadic missing genotypes, we filled in the expected risk allele counts based on the allele frequencies in the parents. As both sets of risk score models were able to accommodate genotypes for imputed SNPs that were not whole numbers, we assigned individual genotypes for imputed SNPs based on expected allele counts.
The relative risk estimates for the 77 SNPs included in the risk score were taken from a study by Mavaddat et al. [60] . These estimates were calculated using data from a pooled analysis with 33,673 cases. None of the 77 selected SNPs was in high linkage disequilibrium (LD) with another included SNP (all r 2 \ 0.80) [60] . To assess model fit and risk score utility, we calculated four p values for each SNP set: an additive score testing b = 0; an additive-fit score testing b = 1; a multiplicative score testing b = 0; and a multiplicative-fit score testing b = 1. Additionally, we compared scores between sisterpairs to assess their ability to predict risk. We also tested for maternally mediated genetic effects by comparing scores of mothers to scores of fathers in families where both parents were genotyped (n = 418).
As a natural extension and a means to further examine risk score utility, we also used logistic regression to examine whether the mothers' scores were associated with their own breast cancer risk. Cases included 119 mothers with breast cancer at any age (cases) versus 599 mothers with no history of breast cancer (controls).
Results
At diagnosis, most of the 1279 cases from the 1296 nonHispanic white families included in our analysis were aged 40-49 (89%) and premenopausal (93%) ( Table 2 ). The proportions of invasive, ER?, and recognized BRCA1/2 mutation positive cases were 84, 81, and 8%, respectively.
Seventeen of the candidate SNPs were associated with increased risk of young-onset breast cancer (p value\0.05; Table 3 ). As demonstrated by the quantile-quantile plot (Fig. 1) , the distribution of p values for the candidate SNPs was markedly shifted relative to the uniform distribution expected under a global null for the set. The SNP with the smallest p value was rs3803662-A, which is located upstream of TOX3 (RR = 1.39, 95% CI 1.20-1.60; p = 7.0 9 10 -6 ). The next smallest p values were for rs12662670-G in ESR1 (RR = 1.56, 95% CI 1.20-2.03; p = 5.7 9 10 -4 ), rs2981579-A in FGFR2 (RR = 1.24, 95% CI 1.08-1.42; p = 0.002), and rs999737-G in RAD51B (RR = 1.27, 95% CI 1.09-1.48; p = 0.003).
The remaining 13 SNPs with statistically significant associations are located in the following loci: ESR1, 2q14.2, TERT, ARHGEF5, 10q26.12, CCND1, MKL1, 9q31.2, MRPS30, 8q24.21, PEX14, and ADAM29. The ESR1 and 8q24.21 regions both had two statistically significant SNPs which were not in LD with one another. When we compared our observed effect estimates for young-onset breast cancer to those observed for overall breast cancer [60] , the distribution of p values for those tests did not deviate from the expected distribution under the null of no difference (Supplementary Figure S1) .
Analyses restricted to families with invasive, ER?, premenopausal cancer or not known to carry risk-related BRCA1/2 mutations showed similar patterns, with small p values again seen for rs3803662, rs12662670, rs2981579, rs999737, and other top-ranked SNPs from the overall analysis (Supplementary Tables S1-S4 ). For maternally mediated effects, we found only five SNPs associated (p \ 0.05) with young-onset breast cancer, a number compatible with random chance (73 included SNPs, Table 4 and Fig. 2) . None of those SNPs were also identified as significant in our primary analysis.
For the polygenic risk score, both the multiplicative and additive genetic risk scores were associated with youngonset breast cancer (p = 2.7 9 10 -10 and p = 1.3 9 10 -10 , respectively, testing b = 0). The coefficient for the additive risk score was different from 1.0 (b = 5.1, additive-fitp = 2.2 9 10 -7 ), but the coefficient for the multiplicative risk score was not (b = 0.85, multiplicative-fit-p = 0.27). This indicates that the overall joint effect of these risk SNPs was more than additive and consistent with multiplicative and that each one-unit increase in score corresponds to a relative risk increase of 2.34 (e 0.85 ). For both scores, the case sister had a higher score than her control/pseudo-control sister in 59% of pairs, suggesting there is within-family predictive power.
There was no evidence that these genetic effects act prenatally through the mother's phenotype, as there was no difference between mothers' and fathers' genetic scores on either the multiplicative or additive scale (p = 0.19 and p = 0.18, for paired testing, respectively). When we tested the association between the polygenic risk score and breast cancer in mothers, the score preformed similarly to our original analysis, with associations seen for both multiplicative (p = 4.6 9 10 -7 ) and additive (p = 4.0 9 10 -7 ) models. The effects were again more than additive and consistent with multiplicative (multiplicative b = 0.88, multiplicative-fit p = 0.50; additive b = 5.4, additive-fit p = 3.5 9 10 -5 ), with an estimated area under the receiver operating characteristics curve of 0.65 for both formulations.
Discussion
The purpose of this family-based genetic study was to examine whether previously identified breast cancer risk variants were associated with young-onset disease through inherited or maternally mediated effects. We focused on 77 common polymorphisms identified in published GWAS [60] . Seventeen of those candidate SNPs were nominally associated with young-onset breast cancer, and a genetic risk score consisting of all 77 SNPs was related to the risk of young-onset breast cancer in daughters and to a history of breast cancer at any age in their mothers. There was no a Families were categorized as BRCA1 or BRCA2 mutation positive if (1) the case sister reported that she had had a positive test or (2) the case sister was not tested but the unaffected sister reported that she had had a positive test evidence that the independent or combined effects of these candidate SNPs was due to a prenatal effect mediated by the maternal genome. The SNPs with the lowest p values were located in wellstudied susceptibility genes-TOX3, ESR1, FGFR2, and RAD51B. The results were similar when we restricted analyses to include only families with invasive, ER?, or premenopausal young-onset breast cancer, or to families without known deleterious BRCA1/2 variants.
TOX3 encodes a nuclear protein that regulates calciumdependent transcription in neurons [66] . Its link to breast cancer is unclear, though there is some evidence that it is a tumor suppressor [66, 67] . Our top hit, rs3803662, was first identified by Easton et al., [7] , with several subsequent GWAS confirming the region's importance [11, 18, 22, 23, [30] [31] [32] . Presence of this variant allele has been linked to lower TOX3 expression levels in breast tumor tissue [68] . Several candidate gene studies also reported risks of similar magnitude for rs3803662-T and young-onset breast cancers [1, 38, 40, 43, 69] . In Ahsan et al.'s [1] young-onset GWAS, TOX3 was one of the identified susceptibility regions, and rs3803662 had the smallest p value for that region. For a more direct comparison of our results to those of Ahsan et al., see Supplementary Table S5 (a comparison of p values for the 83 previously established susceptibility loci selected by Ahsan et al. and our results for the same SNPs) and Supplementary Table S6 (an assessment of other established susceptibility loci not included in Mavaddat et al. [60] , including the novel GWAS hits from Ahsan et al.).
The SNPs with the second and fifth smallest p values, rs12662670 and rs2046210, respectively, are located in the 6q25 region just upstream of ESR1. ESR1 encodes Estrogen Receptor a, a ligand-activated transcription factor crucial to sexual development and reproduction [70] . rs12662670 was previously linked to increased risk of triple-negative breast cancer, a subtype more common in younger women [71] . We did not have enough cases of triple-negative cancer for a separate analysis. Carriers of the other SNP, rs2046210-A, have lower ESR1 levels in both tumor and normal breast tissue [72] . The 6q25 region was not one of the regions with genome-wide significant p values in Ahsan et al. [1] , though rs2046210-A was positively associated with young-onset breast cancer at p \ 0.05. FGFR2 encodes a fibroblast growth factor receptor, the overexpression of which may contribute to carcinogenesis through increased cell proliferation, migration, and resistance to apoptosis [73] . Our FGFR2 SNP, rs2981579, was first identified by Thomas et al. [31] and independently replicated in two other GWAS [23, 32] . Other GWAS found stronger associations with other SNPs in the same gene [1, 7, 8, 10, 12, 15, 19, 22, 26] . Ahsan et al. [1] , for example, reported genome-wide significant p values for 4 FGFR2 SNPs and young-onset breast cancer, with the smallest p value seen for rs2981579. Other studies have also observed associations between FGFR2 SNPs and young-onset breast cancer [41, 42, 69, 74] .
RAD51B is a homologous recombination repair gene related to BRCA1 and BRCA2 [75] . Thomas et al. [31] were the first to link rs999737-G to breast cancer risk. This was confirmed in a second GWAS [23] and subsequent metaanalysis [76] . Although RAD51B was not one of the genome-wide significant regions identified in Ahsan et al. [1] , rs999737 was associated with young-onset breast cancer at p \ 0.05. In addition to TOX3, ESR1, FGFR2, and RAD51, we corroborated Ahsan et al.'s findings that SNPs in 8q24.21 and 11q13.3 (CCND1) may be important for young-onset breast cancer. However, we did not see statistically significant effects for SNPs in SLC4A7 or MAP3K1. It is not clear whether these differences are due to chance or heterogeneity across studies. We had approximately 80% power to detect RRs of 1.24 or 1.20 for allele frequencies of 20 or 40%, respectively, for a = 0.05. This modest power limits our ability to detect small effects and age-atonset interaction effects. Given this caveat, the results of the statistical tests comparing our effect estimates to those of Mavaddat et al. [60] showed no evidence that effect sizes differed by age at breast cancer onset.
Dite et al. [77] also applied the 77-SNP risk score developed by Mavaddat et al. [60] to evaluate young-onset breast cancer. They reported an area under the curve of 0.61 for the risk score alone, which is consistent with the predictive capability we report here. We additionally found that the 77-SNP risk score was predictive of breast cancer in the mothers of cases (which were predominantly olderonset) and that similar coefficients were seen for the two generations.
Our use of previously reported effect measures helped us avoid overfitting the prediction model to our data [78] and enabled independent replication. Several previous studies have used similar approaches, but most have considered only models with multiplicative joint effects [18, 22, 60, 77, 79] . Like us, Joshi et al. [80] constructed scores for both multiplicative and additive polygenic effects using externally reported effect estimates. We both found evidence that the joint effects were superadditive, but our results showed consistency with a multiplicative model, while Joshi et al. found that the observed associations were submultiplicative. Future studies should consider both additive and multiplicative models to see which mathematical form of the risk score best fits the data and to determine if the same model is appropriate for different subgroups (e.g., younger versus older women). Ideally, investigators will reach a consensus regarding what SNPs to include in the score and how to correctly specify their combined effects. Ultimately, we hope that a risk score can be utilized as a tool to classify women's individual breast cancer risk and identify who should be selected for more or less frequent screening.
A major strength of this study is its family-based design, which is robust to population stratification and amenable to missing-data imputation methods [64, 65] . However, we restricted our analysis to non-Hispanic whites, which somewhat limits the generalizability of our findings. There is also the potential for survival bias if some SNPs are related to survival after breast cancer. However, short-term survival rates for breast cancer are high (91% 5-year relative survival for invasive breast cancer before age 50 [81] ), suggesting the effects of such attrition would be minimal. In this family-based genetic study, we saw little evidence of maternally mediated genetic effects, but found that many of the known breast cancer risk variants were also associated with young-onset breast cancer. Our analyses provide further evidence that certain loci, including TOX3, ESR1, FGFR2, and RAD51B, are important for the development of breast cancer at any age.
